The impact of viral evolution on vaccine development for SARS-CoV-2.

In order to stay circulating in the human population over many years, viruses need to adapt to the environment, mainly to the host's immune response, allowing for reinfection despite preexisting immunity. These different viral strategies are clearly important for guiding vaccine design. SARS-CoV-2 is no exception, using three main strategies to avoid protective and long-lived antibody responses: one very common and two rather unique tactics, consisting of 1) random mutation to partially escape existing antibody responses, 2) increasing affinity of the receptor-binding domain (RBD) of the spike protein to it's receptor Angiotensin-converting enzyme 2 (ACE 2), and 3) diluting out neutralizing epitopes on the viral surface to avoid strong and enduring antibody responses. As the correlate of protection from SARS-CoV-2 is neutralizing antibody response, this review focuses on B cells, the major player in protecting against COVID-19.

Institutions

Publication Details

Journal
Open Access CRIS of the University of Bern
Published
2025-07-18
DOI
https://doi.org/10.48620/89737
Primary Topic
SARS-CoV-2 and COVID-19 Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The impact of viral evolution on vaccine development for SARS-CoV-2.

Open Access CRIS of the University of Bern
SARS-CoV-2 and COVID-19 Research
article

The impact of viral evolution on vaccine development for SARS-CoV-2.

article en

Abstract

In order to stay circulating in the human population over many years, viruses need to adapt to the environment, mainly to the host's immune response, allowing for reinfection despite preexisting immunity. These different viral strategies are clearly important for guiding vaccine design. SARS-CoV-2 is no exception, using three main strategies to avoid protective and long-lived antibody responses: one very common and two rather unique tactics, consisting of 1) random mutation to partially escape existing antibody responses, 2) increasing affinity of the receptor-binding domain (RBD) of the spike protein to it's receptor Angiotensin-converting enzyme 2 (ACE 2), and 3) diluting out neutralizing epitopes on the viral surface to avoid strong and enduring antibody responses. As the correlate of protection from SARS-CoV-2 is neutralizing antibody response, this review focuses on B cells, the major player in protecting against COVID-19.

Open Access CRIS of the University of Bern
Klinik und Poliklinik für Urologie (DE), Center for Rheumatology (US)
Good health and well-being
Openalex Percentile: Top 46%
SARS-CoV-2 and COVID-19 Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.